[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 429,578,048
  • Shares Outstanding, K 1,766,793
  • Annual Sales, $ 61,160 M
  • Annual Income, $ 4,226 M
  • EBIT $ 15,332 M
  • EBITDA $ 24,318 M
  • 60-Month Beta 0.32
  • Price/Sales 6.79
  • Price/Cash Flow 15.51
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 27.43% (+0.22%)
  • Historical Volatility 28.69%
  • IV Percentile 52%
  • IV Rank 53.29%
  • IV High 35.30% on 04/27/26
  • IV Low 18.46% on 08/22/25
  • Expected Move (DTE 6) 6.33 (2.58%)
  • Put/Call Vol Ratio 0.26
  • Today's Volume 34,921
  • Volume Avg (30-Day) 16,181
  • Put/Call OI Ratio 0.73
  • Today's Open Interest 241,214
  • Open Int (30-Day) 250,667
  • Expected Range 239.48 to 252.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 32 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $3.78
  • Number of Estimates 7
  • High Estimate $3.93
  • Low Estimate $3.72
  • Prior Year $2.97
  • Growth Rate Est. (year over year) +27.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
208.99 +18.76%
on 06/02/26
249.58 -0.55%
on 06/26/26
+35.08 (+16.46%)
since 05/26/26
3-Month
190.75 +30.12%
on 04/29/26
249.58 -0.55%
on 06/26/26
+37.08 (+17.56%)
since 03/26/26
52-Week
181.73 +36.58%
on 06/27/25
249.58 -0.55%
on 06/26/26
+61.41 (+32.88%)
since 06/26/25

Most Recent Stories

More News
AbbVie to Host Second-Quarter 2026 Earnings Conference Call

NORTH CHICAGO, Ill. , June 26, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2026 financial results on Friday, July 31, 2026, before the market opens. AbbVie will host...

ABBV : 253.35 (+4.20%)
Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Apogee Therapeutics...

APGE : 132.55 (-0.10%)
ABBV : 253.35 (+4.20%)
BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

IRVINE, Calif. , June 24, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the 2026 cohort of entrepreneurs selected to participate in The Confidence Collective:...

ABBV : 253.35 (+4.20%)
2 Value Stocks Worth Your Attention and 1 Facing Headwinds

2 Value Stocks Worth Your Attention and 1 Facing Headwinds

EFOR : 19.61 (+14.95%)
ALLE : 139.71 (+1.98%)
ABBV : 253.35 (+4.20%)
AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.

Apogee’s rally may be over, but AbbVie’s upside from the deal could just be getting started.

APGE : 132.55 (-0.10%)
$SPX : 7,354.02 (-0.05%)
ABBV : 253.35 (+4.20%)
Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

IRVINE, Calif. , June 23, 2026 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced Health Canada has approved Boey ® (trenibotulinumtoxinE) for the temporary...

ABBV : 253.35 (+4.20%)
AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

NORTH CHICAGO, Ill. , June 23, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission approved MAVIRET ®  (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting...

ABBV : 253.35 (+4.20%)
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

NORTH CHICAGO, Ill. , June 23, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved SKYRIZI ® (risankizumab) for the treatment of children...

ABBV : 253.35 (+4.20%)
The $11 Billion Reason Abbvie Stock Is Up Today

AbbVie stock rallied today on the $10.9 billion acquisition of Apogee Therapeutics. Here’s how you should play ABBV shares at current levels.

APGE : 132.55 (-0.10%)
JNJ : 254.66 (+3.99%)
LLY : 1,208.12 (+7.13%)
ABBV : 253.35 (+4.20%)
REGN : 632.90 (+2.06%)
SNY : 42.95 (+2.75%)
US stocks drift after oil prices ease and Big Tech stocks fall

U.S. stocks drifted through a mixed day of trading after oil prices eased and falling Big Tech stocks weighed on Wall Street

APGE : 132.55 (-0.10%)
AVGO : 365.02 (-3.67%)
$SPX : 7,354.02 (-0.05%)
$DOWI : 51,876.11 (-0.09%)
CME : 221.00 (-1.78%)
ABBV : 253.35 (+4.20%)
$IUXX : 29,118.24 (-1.09%)
AMZN : 232.69 (+2.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strengthening short term outlook on maintaining the current direction.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 258.23
2nd Resistance Point 251.42
1st Resistance Point 247.28
Last Price 253.35
1st Support Level 236.33
2nd Support Level 229.52
3rd Support Level 225.38

See More

Last Price 253.35
52-Week High 249.58
Fibonacci 61.8% 223.66
Fibonacci 50% 215.65
Fibonacci 38.2% 207.65
52-Week Low 181.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.